Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833535 | 0.84 | L3MBTL1 (0.41) | ALDH1A1CHRNB2CHRNA4SMN1; SMN2GAA | |
| SCHEMBL29451360 | 0.84 | ALDH1A1 (0.34) | ALDH1A1TRPV4CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL30094575 | 0.84 | L3MBTL1 (0.41) | ALDH1A1CHRNB2CHRNA4SMN1; SMN2GAA | |
| SCHEMBL23833649 | 0.82 | PDIA6 (0.41) | ALDH1A1KDM4E | |
| SCHEMBL30096955 | 0.82 | PDIA6 (0.41) | ALDH1A1KDM4E | |
| SCHEMBL25316093 | 0.82 | UHRF1 (0.43) | ALDH1A1TRPV4SMN1; SMN2GAAHTT | |
| SCHEMBL23845694 | 0.81 | CDK1 (0.34) | ALDH1A1CHRNB2CHRNA4SMN1; SMN2GAA | |
| SCHEMBL26608096 | 0.79 | TSHR (0.45) | ALDH1A1SMN1; SMN2MAPTKDM4EKMT2A | |
| SCHEMBL23833558 | 0.79 | LMNA (0.43) | ALDH1A1SMN1; SMN2GAAKDM4EHTT | |
| SCHEMBL31584278 | 0.79 | TRPV4 (0.40) | ALDH1A1TRPV4SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4121426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115515948-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021188938-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188938-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | ALDH1A1 3104/4885TRPV4 148/4885CHRNB2 1057/4885 |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | ALDH1A1 2364/4885TRPV4 148/4885CHRNB2 732/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | ALDH1A1 1072/4885TRPV4 4714/4885CHRNB2 4339/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885TRPV4 3580/4885CHRNB2 759/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | ALDH1A1 2366/4885TRPV4 170/4885CHRNB2 955/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | ALDH1A1 1072/4885TRPV4 4714/4885CHRNB2 4339/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885TRPV4 3580/4885CHRNB2 759/4885 |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | ALDH1A1 963/4885TRPV4 3567/4885CHRNB2 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.